Evaluation of a Double-Monoclonal Radioimmunoassay for the
Measurement of Carcinoembryonic Antigen in the Urine of
Patients with Bladder Cancer

Hetherington, J.; Ewing, R.; Cooper, E H

doi:10.1159/000472634

Cited by 12 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…distribution of OD values (p = 0.005). Although this test was mainly qualitative and the number of cases still limited, these data suggest that lBE12-reactive antigen might be a potential urine marker in the follow-up of TCC, distinct from other cancer-related proteins, such as the 50 kDa autocrine motility factor (Guirguis et al, 1988) or carcinoembryonic antigen (Hetherington et al, 1986). The antigen also appears different from the glycolipid antigens recognized by RBS-3 1, RBS-85, and RBA-I MAbs, or the protein antigen defined by HBP-1 MAb (Masuko et al, 1989).…”

Section: Discussionmentioning

confidence: 99%

Histological and urinary reactivity of monoclonal antibody 1be12 in bladder carcinoma. Purification of the antigen from urine

Pancino

Osinaga

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

We have previously reported the production of monoclonal antibody (MAb) 1BE12, which recognizes a glycoprotein in breast-cancer cells. In the present work, 1BE12 reactivity was tested by immunohistochemistry in bladder carcinoma (92 cases) and in non-tumoral bladder samples (15 cases). In 71% of bladder tumors, more than 30% of cells were intensely stained by 1BE12. The percentage of reactive cells was higher in cancers invading the muscle than in more superficial tumors (p = 0.039). In non-tumoral bladder, immuno-staining, when present, was usually confined to the superficial layers with a low number of cells stained (less than 30%) in 13/15 cases. Slot blots, performed on urine samples from 43 bladder-cancer patients and 21 healthy controls, were quantified by densitometry scanning. We found higher optical density (OD) values in urine from muscle-invasive-cancer patients than in urine from more superficial tumors and healthy controls, with a significantly different distribution (p = 0.005). The urinary antigen was detected by immunoblotting with 1BE12 as high-molecular-weight species (greater than 150 kDa). The reactive glycoprotein could thus be purified by immunoaffinity and FPLC filtration from the perchloric-acid-soluble fraction of urine from patients with invasive bladder carcinoma. The availability of purified antigen will allow us to quantitate our assay, in order to evaluate its potential use as a prognostic indicator in bladder-cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Histological and urinary reactivity of monoclonal antibody 1be12 in bladder carcinoma. Purification of the antigen from urine

Pancino

Osinaga

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Urinary basic fetoprotein in the diagnosis and follow-up of patients with urothelial carcinoma

Kigure

Wakayama

Satoh

et al. 1996

Cancer

View full text Add to dashboard Cite

show abstract

Stable Hydrogen‐Bonded Cobalt‐porphyrin Framework for High‐Performance Electrochemical Detection of Carcinoembryonic Antigen

Wang,

Han,

Waterhouse

et al. 2024

Aggregate

View full text Add to dashboard Cite

The accurate and sensitive detection of low‐abundance cancer‐related biomarkers in blood remains a key technical challenge in clinical applications. Herein, a simple and accurate sandwich‐type electrochemical immunosensor based on a stable hydrogen‐bonded cobalt‐porphyrin framework (Co‐HOF) was successfully developed for the ultrasensitive detection of the cancer‐related biomarker, carcinoembryonic antigen (CEA). The antibody‐modified Co‐HOF forms a sandwich structure with the CEA aptamer electrode exclusively in the presence of CEA, enabling the specific electrochemical detection of CEA. The electrochemical signal increased linearly with the concentration of CEA, demonstrating a wide linear range (0.001–50 ng mL−1) and a low detection limit (0.22 pg mL−1), surpassing the performance of commercial ELISA kits and most reported detection methods. The sensor was successfully employed for CEA detection in spiked human serum, with recoveries ranging from 85.04% to 105.20%. Additionally, we collected blood samples from colorectal cancer patients and healthy individuals to clinically validate the sensor, observing that CEA levels increased with cancer progression. The sensor detection results showed strong consistency (R2 = 0.995) with those obtained from commercial ELISA kits, demonstrating the proposed sensor's practicality for clinical detection of CEA and related cancer biomarkers.

show abstract

Evaluation of a Double-Monoclonal Radioimmunoassay for the Measurement of Carcinoembryonic Antigen in the Urine of Patients with Bladder Cancer

Cited by 12 publications

References 10 publications

Histological and urinary reactivity of monoclonal antibody 1be12 in bladder carcinoma. Purification of the antigen from urine

Histological and urinary reactivity of monoclonal antibody 1be12 in bladder carcinoma. Purification of the antigen from urine

Urinary basic fetoprotein in the diagnosis and follow-up of patients with urothelial carcinoma

Stable Hydrogen‐Bonded Cobalt‐porphyrin Framework for High‐Performance Electrochemical Detection of Carcinoembryonic Antigen

Contact Info

Product

Resources

About